Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Truist Securities maintains its Buy rating for Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises its price target from $22.00 to $24.00. Catalyst Pharmaceuticals shares are trading up 3.13% at $13.02 per share.
June 21, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains Buy rating for Catalyst Pharmaceuticals and raises price target to $24.00, a potential 84.4% increase from the current share price.
Truist Securities' decision to maintain its Buy rating and raise the price target for Catalyst Pharmaceuticals is a positive signal for the stock. The new price target represents a significant potential upside of 84.4% from the current share price, which could attract more investors and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100